PHILADELPHIA — It’s well known that humans and other animals are fatigued and sleepy when sick, but it’s a microscopic roundworm that’s providing an explanation of how that occurs, according to a study from researchers at the
Perelman School of Medicine at the University of Pennsylvania. A study published this week in
eLife reveals the mechanism for this sleepiness.
Working with a worm’s simple nervous system shows how a single nerve cell named ALA coordinates an organism-wide response to sickness. During sickness, cells are under stress, and organisms experience sleepiness to promote sleep and recover from the cellular stress. In the worm, this sleepiness is caused by release from the ALA neuron of FLP-13 and other neuropeptides, a group of chemicals that send signals between brain neurons.
“Sleep is vitally important in helping both people and animals to recover during sickness,” said senior author David M. Raizen, MD, PhD, an associate professor of Neurology and a member of the Center for Sleep and Circadian Neurobiology. “Similar signaling may operate in humans and other animals to regulate sleep during sickness. These findings create a launching pad towards future research into the mechanisms for illness-induced sleepiness in humans and other organisms.”
These findings reveal that FLP-13 causes sleep by turning down activity in the nervous system cells that help keep an organism awake. Researchers examined genetic mutations to determine which genes cause the worms to fall asleep when FLP-13 is released. This revealed that worms with mutations that cause them to lack a receptor protein called DMSR-1 on cell surfaces do not become sleepy in response to FLP-13. This indicates that DMSR-1 is essential for FLP-13 to trigger sleep.
Next experiments will target whether illness-induced sleepiness in humans and other mammals is triggered via a similar mechanism. If so, this research may be a critical step towards developing drugs to treat human fatigue associated with sickness and other conditions.
Co-authors include first author Michael Iannacone (University of Pennsylvania), Isabel Beets (KU Leuven of Belgium), Lindsey Lopes (University of Pennsylvania), Matthew Churgin (University of Pennsylvania), Christopher Fang-Yen (University of Pennsylvania), Matthew Nelson (Saint Joseph's University), and Liliane Schoofs (KU Leuven of Belgium).
Funding was provided by the National Institutes of Health R01NS088432, R21NS091500, and P30ES013508, the European Research Council ERC-2013-ADG-340318, and the Fonds Wetenschappelijk Onderzoek.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.